Expression and prognostic significance of cyclin‑dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma

Abstract

Abstract. Cyclin-dependent kinase inhibitor 1A (CDKN1A) is an important cell cycleregulator, and has been identified to exhibit aberrant expression in various types of cancer tissues. However, the association between CDKN1A expression level and prognosis in patients with resected gastric adenocarcinoma (RGA) requires additional elucidation. In the present study, the CDKN1A expression profile in RGA tissues obtained from 217 patients were analyzed using immunohistochemistry. Its prognostic significance was evaluated by using the χ 2 test, Kaplan-Meier curves and the log-rank test, and a multivariate Cox model analysis, during a median follow-up time of 51 months. The results demonstrated that CDKN1A expression was significantly correlated with lymph node metastasis (LNM; P=0.001), recurrence (P<0.001) and overall survival (OS; P<0.001). In addition, the recurrence-free survival (RFS) and OS times were significantly shorter in patients with low CDKN1A expression compared with those with high CDKN1A expression (RFS, 20 months vs. 69 months, P<0.001; and OS, 32 months vs. 70 months, P<0.001, respectively). Multivariate analysis additionally confirmed that low CDKN1A expression was significantly correlated with an increased risk of LNM (P=0.001), recurrence (P<0.001) and mortality (P<0.001). Therefore, these data suggest that low expression of CDKN1A has independent prognostic significance indicative of tumor progression and poor survival in patients with RGA. Evaluation of CDKN1A expression may assist in determining prognosis in patients with RGA.

Identification of key pathways and genes in colorectal cancer to predict the prognosis based on mRNA interaction network

“…Therefore, CDKN1A is an indicator of tumor characteristics and may be used to predict patient prognosis. A previous study also indicated that differential expression of CDKN1A affected prognosis in the survival analysis of patients with gastric cancer (44). In this study, the GSE21510 and GSE32323 datasets were analyzed.…”

Pyrogallol Suppresses the Tumor Progression via Modulating Aerobic Glycolysis and STAT2 Signaling Pathway in Non-small Cell Lung Carcinoma

“…It involves in G2/M checkpoint that contributes to resistance to Taxol-induced apoptosis in ERBB2-overexpressed breast cancer cells (Kreis et al, 2019). Moreover, CDKN1A has demonstrated important prognostic significance and may be used as an independent prognostic factor for patients with RGA (Lin et al, 2017). In our study, we analyzed the molecular interaction of pyrogallol with p21 protein, with a binding energy value of −3.79 kcal/mol, and in vitro study shows that pyrogallol suppresses the expression of p21.…”